Kymera Therapeutics (NASDAQ:KYMR) Coverage Initiated by Analysts at Stephens

Equities research analysts at Stephens initiated coverage on shares of Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) in a note issued to investors on Monday, MarketBeat.com reports. The firm set an "overweight" rating and a $65.00 price target on the stock. Stephens' target price would indicate a potential upside of 53.27% from the stock's previous close.

A number of other analysts also recently issued reports on KYMR. Morgan Stanley lifted their price target on Kymera Therapeutics from $45.00 to $49.00 and gave the company an "equal weight" rating in a research report on Wednesday, November 6th. Leerink Partners reissued an "outperform" rating and issued a $60.00 price target on shares of Kymera Therapeutics in a report on Monday, September 9th. Guggenheim raised their price objective on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a "buy" rating in a research report on Friday, November 1st. Wolfe Research raised Kymera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $65.00 target price on the stock in a research note on Monday, August 26th. Finally, Oppenheimer raised their price target on Kymera Therapeutics from $52.00 to $56.00 and gave the company an "outperform" rating in a research report on Friday, September 27th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $52.13.

Kymera Therapeutics Stock Performance

Kymera Therapeutics stock traded up $0.45 during mid-day trading on Monday, reaching $42.41. The company's stock had a trading volume of 403,289 shares, compared to its average volume of 588,997. The company has a market capitalization of $2.75 billion, a P/E ratio of -17.93 and a beta of 2.21. The firm's fifty day moving average price is $47.17 and its two-hundred day moving average price is $41.72. Kymera Therapeutics has a 12-month low of $18.89 and a 12-month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $3.74 million for the quarter, compared to analyst estimates of $10.34 million. During the same quarter in the prior year, the firm posted ($0.90) EPS. Kymera Therapeutics's revenue was down 20.9% on a year-over-year basis. On average, research analysts predict that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In related news, Director Pamela Esposito sold 13,500 shares of the stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey W. Albers sold 5,000 shares of the firm's stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The disclosure for this sale can be found here. Corporate insiders own 15.82% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. increased its stake in shares of Kymera Therapeutics by 7.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company's stock worth $164,000 after acquiring an additional 295 shares in the last quarter. Comerica Bank increased its stake in shares of Kymera Therapeutics by 13.7% during the first quarter. Comerica Bank now owns 3,324 shares of the company's stock valued at $134,000 after purchasing an additional 400 shares in the last quarter. Keudell Morrison Wealth Management lifted its holdings in shares of Kymera Therapeutics by 7.2% during the second quarter. Keudell Morrison Wealth Management now owns 7,105 shares of the company's stock valued at $212,000 after purchasing an additional 480 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company's stock worth $114,000 after purchasing an additional 504 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Kymera Therapeutics by 8.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company's stock worth $534,000 after buying an additional 915 shares during the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.